Last reviewed · How we verify

POHERDY (PERTUZUMAB-DPZB)

SHANGHAI HENLIUS BIOTECH · FDA-approved approved

POHERDY (generic name: PERTUZUMAB-DPZB) is a drug developed by SHANGHAI HENLIUS BIOTECH. It is currently FDA-approved.

At a glance

Generic namePERTUZUMAB-DPZB
SponsorSHANGHAI HENLIUS BIOTECH
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about POHERDY

What is POHERDY?

POHERDY (PERTUZUMAB-DPZB) is a pharmaceutical drug developed by SHANGHAI HENLIUS BIOTECH.

Who makes POHERDY?

POHERDY is developed and marketed by SHANGHAI HENLIUS BIOTECH (see full SHANGHAI HENLIUS BIOTECH pipeline at /company/shanghai-henlius-biotech).

What is the generic name of POHERDY?

PERTUZUMAB-DPZB is the generic (nonproprietary) name of POHERDY.

What development phase is POHERDY in?

POHERDY is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing